Treats skin and skin structure infections caused by Escherichia coli, Klebsiella…. ANDA 76639, held by UNIQUE. Ciprofloxacin Hydrochloride.
As of Nov 21, 2026, ANDA 76639 (Ciprofloxacin Hydrochloride), held by UNIQUE, was first approved by FDA on Sep 10, 2004, with 19 approved supplements and 0 published complete response letters.
Ciprofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections Bone and Joint Infections Complicated Intra-Abdominal Infections Infectious Diarrhea Typhoid Fever (Enteric Fever) Uncomplicated Cervical and Urethral Gonorrhea Inhalational Anthrax post-exposure in adult and pediatric patients Plague in adult and pediatric patients Chronic Bacterial Prostatitis Lower Respiratory Tract Infections o Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections o Urinary Tract Infections (UTI) o Acute Uncomplicat…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2004 | Original application | Approved | None posted |
| Ciprofloxacin HydrochlorideEQ 250MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Rx |
| Ciprofloxacin HydrochlorideEQ 500MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Rx |
| Ciprofloxacin HydrochlorideEQ 750MG BASE · tablet;oral | Ciprofloxacin Hydrochloride | Rx |
| Dec 17, 2025 | Supplement 33Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 30Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 29Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 27Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 22Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 19Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 18Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 15Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 19, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 22, 2013 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jul 25, 2012 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 29, 2012 | Supplement 8Labeling | Approved | None posted |
| Nov 28, 2011 | Supplement 7Labeling | Approved | None posted |
| May 16, 2011 | Supplement 6Labeling | Approved | None posted |
| Mar 9, 2010 | Supplement 2Labeling | Approved | None posted |
| Sep 10, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters